Guerbet announced that Cincinnati Children’s Hospital Medical Center performed the first US injection of Dotarem (gadoterate meglumine), the only macrocyclic and ionic gadolinium-based contrast agent (GBCA) approved by the US Food and Drug Administration. The procedure was performed in a school-aged child.
Dotarem is indicated for intravenous use with MRI in brain, spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Dotarem has been commercialized widely outside the US since 1989 and has had more than 37 million doses administered.
